Company profile
Verastem, Inc.
NASDAQ: VSTM · Healthcare · Biotechnology
#500 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
49DFH 33DQ 56GM 71SS 68
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ return on equity, net margin
Methodology →Revenue TTM
$49.6M
Rev growth YoY (TTM)
+395.8%
Net income (FY)
-$209.5M
Employees
102
as of 2026-08-13
Market cap
$610.7M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$30.9M$30.9M2025
Net income-$209.5M-$209.5M2025
Operating income-$170.1M-$170.1M2025
Total assets$246.4M$246.4M2025
Liabilities$189.2M$189.2M2025
Equity$57.2M$57.2M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY20
FY21
FY22
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Government rebates and other incentives78%
Trade discounts and allowances16%
Returns7%
By geography
Not disclosed.
The read
What is Verastem, Inc.’s revenue?
Verastem, Inc. booked $30.9M in FY2025 revenue, growing 209% year over year — faster than most Healthcare companies we track, at a -677.6% net margin.
Peers · Healthcare
Sonendo, Inc.——Cryo-Cell International, Inc.63CEyePoint Pharmaceuticals, Inc.58CFoghorn Therapeutics Inc.47DScripsAmerica, Inc.——BioSyent Inc.83B+Neighbors
Norfolk →Key facts
CEODaniel W. Paterson
SectorHealthcare
IndustryBiotechnology
HeadquartersNeedham, MA
ExchangeNASDAQ: VSTM
Employees102
IPO date2012-01-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.